; or (II) intended to reach a minority, ethnic, or other special audience that cannot reasonably be obtained at no cost. (ii) Testing and evaluation of advertising In using amounts for testing and evaluation of advertising under subparagraph (A)(iv), the Director shall test all advertisements prior to use in the national media campaign to ensure that the advertisements are effective with the target audience and meet industry-accepted standards. The Director may waive this requirement for advertisements using no more than 10 percent of the purchase of advertising time purchased under this subsection in a fiscal year and no more than 10 percent of the advertising space purchased under this subsection in a fiscal year, if the advertisements respond to emergent and time-sensitive campaign needs or the advertisements will not be widely utilized in the national media campaign. (iii) Consultation For the planning of the campaign under paragraph (1), the Director may consult with— (I) the head of any appropriate National Drug Control Program Agency; (II) experts on the designated drug; (III) State, local, and Tribal government officials and relevant agencies; (IV) communications professionals; (V) the public; and (VI) appropriate congressional committees. (iv) Evaluation of effectiveness of national media campaign In using amounts for the evaluation of the effectiveness of the national media campaign under subparagraph (A)(v), the Director shall— (I) designate an independent entity to evaluate by April 20 of each year the effectiveness of the national media campaign based on data from— (aa) the Monitoring the Future Study published by the Department of Health and Human Services; (bb) the National Survey on Drug Use and Health; and (cc) other relevant studies or publications, as determined by the Director, including tracking and evaluation data collected according to marketing and advertising industry standards